Cochrane · systematic review · CD001100

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism

Robertson, L, Jones, LE · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library

VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 5 · 83.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

LMWH compared to UFH for initial treatment of venous thromboembolism

Population: people with venous thromboembolism (VTE)
6 questions
OutcomeEffectEvidenceStatus / GRADE
Incidence of recurrent VTE1 after initial treatment (up to 15 days)
LMWH vs UFH
OR 0.69 [0.49, 0.98]18 studies · 6238 participantsModerate
Downgraded: risk of bias
Incidence of recurrent VTE1 (3 months
LMWH vs UFH
OR 0.71 [0.56, 0.9]16 studies · 6661 participantsModerate
Downgraded: risk of bias, imprecision
Incidence of recurrent VTE1 (end of
LMWH vs UFH
OR 0.72 [0.59, 0.88]22 studies · 9489 participantsModerate
Downgraded: risk of bias
Reduction in thrombus size (pre‐ and post‐treatment venograms)
LMWH vs UFH
OR 0.71 [0.61, 0.82]16 studies · 2909 participantsLow
Downgraded: risk of bias, imprecision, inconsistency
Incidence of major haemorrhagic episodes (during initial treatment ‐ up to 15 days)
LMWH vs UFH
OR 0.69 [0.5, 0.95]25 studies · 8780 participantsModerate
Downgraded: risk of bias, imprecision
Overall mortality (end of
LMWH vs UFH
OR 0.84 [0.7, 1.01]24 studies · 9663 participantsModerate
Downgraded: risk of bias, imprecision